Coagulation activation in young survivors of myocardial infarction (MI) - a population-based case-control study

Ellen Brodin; Trond Børvik; Per Morten Sandset; Kaare H. Bønaa; Arne Nordøy; John-Bjarne Hansen

doi:10.1160/TH03-11-0674

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2004; 92(01): 178-184
DOI: 10.1160/TH03-11-0674

Cell Signalling and Vessel Remodelling

Schattauer GmbH

Coagulation activation in young survivors of myocardial infarction (MI) - a population-based case-control study

Authors

Ellen Brodin

¹Center for Atherothrombotic Research in Tromsø (CART), Department of Medicine, Institute of Clinical Medicine, University of Tromsø,Tromsø, Norway
Trond Børvik

¹Center for Atherothrombotic Research in Tromsø (CART), Department of Medicine, Institute of Clinical Medicine, University of Tromsø,Tromsø, Norway
Per Morten Sandset

²Haematological Research Laboratory, Medical Clinic, Ullevaal University Hospital, Oslo, Norway
Kaare H. Bønaa

³Institute of Community Medicine, University of Tromsø,Tromsø, Norway
Arne Nordøy

¹Center for Atherothrombotic Research in Tromsø (CART), Department of Medicine, Institute of Clinical Medicine, University of Tromsø,Tromsø, Norway
John-Bjarne Hansen

¹Center for Atherothrombotic Research in Tromsø (CART), Department of Medicine, Institute of Clinical Medicine, University of Tromsø,Tromsø, Norway

Abstract

Summary

Formation of an occlusive thrombus by exposure of tissue factor (TF) to circulating blood and subsequent triggering of coagulation by TF-FVIIa complexes on ruptured atherosclerotic plaques is thought to be a key event in acute MI. Tissue factor pathway inhibitor (TFPI) is a potent inhibitor of TF-induced coagulation by neutralizing FXa and inhibiting the TF-FVIIa complex. A case control study was conducted to investigate the role of coagulation activation in MI. Sixty-two patients with verified MI, 40-60 yrs of age, were recruited into the study and examined 1-4 years after the acute coronary event. Thrombinantithrombin complex (TAT) was significantly increased in MI patients (8.2 ± 12.9 µg/l vs. 3.9 ± 2.6 µg/l, p=0.01). In contrast, FVIIa was lower in MI patients (41 ± 13 mU/ml vs. 48 ± 15 mU/ml, p=0.003) accompanied by an increase in plasma free TFPI antigen (20.9 ± 5.0 ng/ml vs. 19.2 ± 4.9 ng/ml, p=0.03). Significant trends for increase in triglycerides and total cholesterol across quartiles of free TFPI Ag were found in both groups, whereas HDL cholesterol decreased across quartiles of TFPI among control subjects. The compensatory increase in plasma free TFPI with established lipid and haemostatic risk factors were abrogated in the MI patients. An apparent increase in the basal activation of the coagulation system was observed in young patients with MI. Enhanced coagulation activation was accompanied by a decrease in FVIIa and increase in free TFPI Ag, probably reflecting a modest triggering of TF-induced coagulation in these patients.

Keywords

Tissue factor pathway inhibitor (TFPI) - tissue factor / factor VII - ischaemic heart disease - thrombin

Full Text

References

References
1 Tremoli E, Camera M, Toschi V. et al. Tissue factor in atherosclerosis. Atherosclerosis 1999; 144: 273-83.
2 Fuster V, Badimon L, Badimon JJ. et al. The pathogenesis of coronary artery disease and the acute coronary syndrome. N Engl J Med 1992; 326: 310-8.
3 Wilcox JN, Smith KM, Schwartz SM. et al. Localization of tissue factor in normal vessel and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-43.
4 Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-4.
5 Suefuji K, Ogawa H, Yasue H. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997; 134: 253-9.
6 Misumi K, Ogawa H, Yasue H. Comparison of plasma tissue factor levels in unstable and stable angina pectoris. Am J Cardiol 1998; 81: 22-6.
7 Broze Jr. GJ, Warren LA, Novotny WF. et al. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action. Blood 1988; 71: 335-43.
8 Warn-Cramer BJ, Rao LVM, Maki SL. et al. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: evidence for a two-step model of inhibition. Thromb Haemost 1988; 60: 453-6.
9 Van de Loo J. Annotation. Circulating factors of the haemostatic system as indicators of increased or reduced coronary risk. Br J Haematol 1995; 91: 777-82.
10 Bajaj MS, Kuppuswamy MN, Saito H. et al. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869-73.
11 Falciani M, Gori AM, Fedi S. et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischemic heart disease patients. Thromb Haemost 1998; 79: 495-9.
12 Nakagaki T, Foster DC, Berkner KL. et al. Initiation of the extrinsic pathway of blood coagulation: evidence for the tissue factor dependent auto activation of human coagulation factor VII. Biochemistry 1991; 30: 10819-24.
13 de Sousa JCarvalho, Azvedo J, Soria C. et al. Factor VII hyperactivity in acute myocardial thrombosis: a relation to the coagulation activation. Thromb Res 1988; 51: 165-73.
14 Miller GJ, Bauer KA, Barzegar S. et al. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost 1996; 75: 767-77.
15 Moor E, Silveira A, Hooft FV. et al. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype. Arterioscler Thromb Vasc Biol 1995; 15: 655-64.
16 Merlini PA, Bauer K, Oltrona L. et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994; 90: 61-8.
17 Li YH, Teng JK, Tsai WC. et al. Prognostic significance of elevated haemostatic markers in patients with acute myocardial infarction. J Am Coll Cardiol 1999; 33: 1543-8.
18 Peternel P, Terbizan M, Tratar G. et al. Markers of haemostatic system activation during treatment of deep vein thrombosis with subcutaneous unfractionated or low molecular weight heparin. Thromb Res 2002; 105: 241-6.
19 Burstein M, Scholnick HR, Mofin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyamines. J Lipid Res 1970; 11: 583-95.
20 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifugation. Clin Chem 1972; 18: 499-502.
21 Sandset PM, Larsen ML, Abildgaard U. et al. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis 1991; 2: 425-33.
22 Østergaard PB, Beck TC, Ørsted H. et al. An enzyme linked immunosorption assay for tissue factor pathway inhibitor. Thromb Res 1997; 87: 447-59.
23 Morrisey JH, Marci BG, Neuenschwander PF. et al. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
24 Ottani F, Galvani M. Prognostic role of haemostatic markers in acute coronary syndrome patients. Clinica Chimica Acta 2001; 311: 33-9.
25 Danielsen R, Onundarson P, Thors H. et al. Activated and total coagulation factor VII, and fibrinogen in coronary artery disease. Scand Cardiovasc 1998; 32: 87-95.
26 Moor E, Silveira A, Hooft FV. et al. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Arterioscler Thromb Vasc Biol 1995; 15: 655-64.
27 Cooper JA, Miller GJ, Bauer KA. et al. Comparison of novel hemostatic factors and conventional risk factors for prediction of coronary heart disease. Circulation 2000; 102: 2816-22.
28 Golino P. The inhibitors of the tissue factor: factor VII pathway. Thromb Res 2002; 106: 257-65.
29 Mesters RM, Mannucci PM, Coppola R. et al. Factor VIIa and antithrombin III activity during servere sepsis and septic shock in neutropenic patients. Blood 1996; 88: 881-6.
30 Rapaport SI, Rao LVM. The tissue factor pathway: How it has become a “prima ballerina”. Thromb Haemost 1995; 74: 7-17.
31 Almus FE, Rao LVM, Rapaport SI. Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model. Arterioscler Thromb Vasc Biol 1993; 13: 105-11.
32 Kawaguchi A, Miyao Y, Noguchi T. et al. Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase but proportional to apolipoprotein A-II. Arterioscler Thromb Vasc Biol 2000; 20: 251-8.
33 Saigo M, Abe S, Ogawa M. et al. Imbalance of plasminogen activator inhibitor -1/tissue plasminogen activator and tissue factor/ tissue factor pathway inhibitor in young Japanese men with myocardial infarction. Thromb Haemost 2001; 86: 1197-203.
34 Hansen JB, Grimsgaard S, Huseby NE. et al. Serum lipids and regulation of tissue factor-nduced coagulation in middle-aged men. Thromb Res 2001; 102: 3-13.
35 Hansen JB, Huseby NE, Sandset PM. et al. Tissue factor pathway inhibitor and lipoproteins: evidence for association with and regulation by LDL in human plasma. Arterioscler Thromb Vasc Biol 1994; 14: 223-9.
36 Kokawa T, Abumiya T, Kimura T. et al. Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipidemia. Arterioscler Thromb Vasc Biol 1995; 15: 504-10.